Muir-Torre syndrome - treatment with isotretinoin and interferon alpha-2a can prevent tumour development.

Abstract

Muir-Torre syndrome is a genodermatosis in which multiple internal malignancies are associated with cutaneous sebaceous tumours and kerato-acanthomas. A 57-year-old man presented with multiple sebaceous tumours, kerato-acanthomas, verrucous carcinoma of the nose, renal cell and transitional cell carcinomas of the left kidney, adenoma of the colon and a positive family history of colon carcinoma. He was treated with interferon (IFN-alpha2a) s.c. 3 x 10(6) U three times a week along with 50 mg isotretinoin daily as well as topical isotretinoin gel. During a follow-up of 29 months, only 1 sebaceous skin tumour developed and was removed, whereas more than 30 such skin tumours had been surgically removed during the last 3 years. No evidence of internal tumour development or recurrence was found. The combination of IFN with retinoids seems to be of promise to prevent tumour development in Muir-Torre syndrome.

• Authors: T Graefe, U Wollina, H Schulz, W Burgdorf
• Journal: Dermatology (Basel, Switzerland) (Dermatology) Vol. 200 Issue 4 Pg. 331-3 ( 2000) ISSN: 1018-8665 [Print] Switzerland
• PMID: 10894967 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright 2000 S. Karger AG, Basel

Chemical References

• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Isotretinoin

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Humans
• Interferon alpha-2
• Interferon-alpha (administration & dosage)
• Isotretinoin (administration & dosage)
• Male
• Middle Aged
• Neoplasms, Multiple Primary (drug therapy, pathology)
• Recombinant Proteins
• Sebaceous Gland Neoplasms (drug therapy, pathology)
• Skin (drug effects, pathology)
• Syndrome